1.Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27:165.
2.Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350:1655.
3.Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001; 91:1191.
4.Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12:6243s.
5.Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2:584.
6.Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9:239.
7.Meads MB, Hazlehurst LA, Dalton WS. The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance. Clinical Cancer Research. 2008; 14:2519.
8.Taghavi Pourianazar N, Mutlu P, Gunduz U. Bioapplications of poly(amidoamine) (PAMAM) dendrimers in nanomedicine. Journal of Nanoparticle Research. 2014; 16:2342.
9.Cheng Y, Zhao L, Li Y, Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev. 2011; 40:2673.
10.Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Applied Materials Today. 2018; 12:177.
11.Li N, Song J, Zhu G, Shi X, Wang Y. Alendronate conjugated nanoparticles for calcification targeting. Colloids Surf B Biointerfaces. 2016; 142:344.
12.Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:10287.
13.Katrin Hochdörffer, Khalid Abu A, Cynthia Schafer-O, Felix K. Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix. Journal of Medicinal Chemistry. 2012; 55:7502.
14.de Miguel L, Noiray M, Surpateanu G, Iorga BI, Ponchel G. Poly(gamma-benzyl-L-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting. Int J Pharm. 2014; 460:73.
15.Ramanlal Chaudhari K, Kumar A, Megraj Khandelwal VK, Ukawala M, Manjappa AS, Mishra AK, et al. Bone metastasis targeting: A novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. Journal of Controlled Release. 2012; 158:470.
16.Liu N, Bechinger B, Süss R. The histidine-rich peptide LAH4-L1 strongly promotes PAMAM-mediated transfection at low nitrogen to phosphorus ratios in the presence of serum. Scientific Reports. 2017; 7:9585.
17.Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers MM. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm. 2007; 345:142.
18.Hsu HJ, Bugno J, Lee SR, Hong S. Dendrimer-based nanocarriers: a versatile platform for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017; 9.
19.Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews. 2016; 99:28.
20.Bai SB, Liu DZ, Cheng Y, Cui H, Liu M, Cui MX, et al. Osteoclasts and tumor cells dual targeting nanoparticle to treat bone metastases of lung cancer. Nanomedicine. 2019; 21:102054.
21.Labieniec-Watala M, Watala C. PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications. J Pharm Sci. 2015; 104:2.
22.Lu Y, Han S, Zheng H, Ma R, Ping Y, Zou J, et al. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system. International Journal of Nanomedicine. 2018; Volume 13:5937.
23.Luong D, Kesharwani P, Deshmukh R, Amin MCIM, Gupta U, Greish K, et al. PEGylated PAMAM Dendrimers: Enhancing Efficacy and Mitigating Toxicity for Effective Anticancer Drug and Gene Delivery. Acta Biomaterialia. 2016; 43:14.
24.Tang L, Fan TM, Borst LB, Cheng J. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. ACS Nano. 2012; 6:3954.
25.Hu W, Cheng L, Cheng L, Zheng M, Lei Q, Hu Z, et al. Redox and pH-responsive poly (amidoamine) dendrimer-poly (ethylene glycol) conjugates with disulfide linkages for efficient intracellular drug release. Colloids Surf B Biointerfaces. 2014; 123:254.
26.Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Kusamori K, et al. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases. Journal of Controlled Release. 2017; 262:10.
27.Thamake SI, Raut SL, Gryczynski Z, Ranjan AP, Vishwanatha JK. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 2012; 33:7164.
28.Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 2008; 42:848.
29.Low SA, Kopecek J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev. 2012; 64:1189.
30.Currie GL, Delaney A, Bennett MI, Dickenson AH, Egan KJ, Vesterinen HM, et al. Animal models of bone cancer pain: Systematic review and meta-analyses. Pain. 2013; 154:917.
31.Anada T, Takeda Y, Honda Y, Sakurai K, Suzuki O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorganic & Medicinal Chemistry Letters. 2009; 19:4148.
32.Russ V, Günther M, Halama A, Ogris M, Wagner E. Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. Journal of Controlled Release. 2008; 132:131.
33.Zhao YP, Ye WL, Liu DZ, Cui H, Cheng Y, Liu M, et al. Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption. Nanoscale. 2017; 9:6264.
34.Jiao Z, Xu W, Zheng J, Shen P, Qin A, Zhang S, et al. Kaempferide Prevents Titanium Particle Induced Osteolysis by Suppressing JNK Activation during Osteoclast Formation. Sci Rep. 2017; 7:16665.
35.Zhao N, Nociti FH, Jr., Duan P, Prideaux M, Zhao H, Foster BL, et al. Isolation and Functional Analysis of an Immortalized Murine Cementocyte Cell Line, IDG-CM6. J Bone Miner Res. 2016; 31:430.
36.Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988; 48:6876.
37.Vermeirsch H, Nuydens RM, Salmon PL, Meert TF. Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity. Pharmacol Biochem Behav. 2004; 79:243.